Contraception refers to a method of avoiding pregnancy with the use of drugs or devices. It is also referred to as birth control or fertility control. The market for contraceptives is anticipated to witness healthy growth over the next five years. The market growth may be attributed to numerous factors, out of which growing consumer consciousness regarding STDs, population control, and unintended pregnancies are some of the prime factors that have escalated the demand for contraceptive drugs and devices, particularly in the emerging economies of the globe. Moreover, the growing government focus in many countries on population control has further created business growth opportunities for market players over the next five years. The government around the globe is playing a significant role in shaping the market growth as various campaigns and programs are being carried out to make people aware of contraception and birth control. For instance, the National Programme for Family Planning, under the Ministry of Health and Family, of the Government of India, aims to reduce the overall fertility rate of the country to 2.1 by the year 2025. The key strategies of the program also include providing more choices through newly introduced contraceptives such as injectable contraceptives, MPA (Medroxyprogesterone acetate) under the Antara program, and Chaya oral contraceptive pills are to be made freely available to all the government hospitals of the country. The growing working-class female population is also a key factor supplementing the market growth over the next five years.
However, the health risks associated with the consumption of pills, coupled with the lack of awareness about contraception in underdeveloped economies, are some of the key factors hampering the market growth during the next five years. Moreover, the outbreak of COVID-19 had a moderate impact on the market growth since the demand for devices and pills decreased during the pandemic.
High cases of unintended pregnancies drive the growth.
The primary factor propelling the demand for contraceptive devices and drugs is the globally growing number of unintended or mistimed pregnancy cases worldwide. As per the study from the World Health Organization in 36 countries, promiscuous women who wished to delay did not use contraception which further led to a case of one in four pregnancies being unintended. The study also found that 9.9% of the total women in the study had unintended pregnancies. Lack of education and low awareness about contraception in some economies and restricted access to devices and drugs are some of the major factors propelling the number of cases of unwanted pregnancies. However, governments play a significant role in making people aware of these products and educating them regarding proper family planning through programs and campaigns. Thus, the number of unwanted pregnancy cases plays a considerable role in supplementing the contraceptive market growth during the forecast period.
Health risks associated with contraceptionThe health risk associated with the consumption of pills and other devices may restrict their demand to some extent, which is considered a negative factor for the market growth over the next five years. There are several side effects of oral pills, such as nausea, migraine, severe abdominal pain, etc. All such factors make women reluctant towards their consumption. However, the consumption of oral pills also may fail to give 100% results.
Drugs to witness promising growth during the next five yearsBy product, the market classification has been done into drugs and devices. The drugs segment is further distributed into pills, injectables, and topical contraceptives, and the devices segment is distributed as condoms, IUDs, diaphragms, rings, and others. The devices segment is projected to hold a substantial share in the market throughout the course of the next five years owing to the high use of devices such as condoms, sponges, and diaphragms, among others, as a means of reducing the risks of STDs and for birth control as well. Moreover, the growing awareness among the people living in developing economies regarding the use of condoms and government policies and programs aimed toward the use of condoms to promote safe intercourse are some of the major factors supporting the demand as well as the growth of this segment over the course of the next five years. On the other hand, the drugs segment is projected to witness substantial growth during the next five years, which may be attributed to the growth of the millennial population in many parts of the world.
Covid-19 Impact on The Contraceptive Market
According to information from the Clinton Health Access Initiative (CHAI) and the Reproductive Health Supplies Coalition (RHSC), risen sourcing of injectables, implants, and contraceptive pills pushed market growth, which attained US$261 million in 2020 across 69 countries, with market volumes increasing by 23 percent during the forecasted period. Amidst the COVID-19 disease outbreak, the significance of the public-sector contraceptive segment surpassed a five-year high in 2020. While COVID-19 posed hurdles to medical distribution networks and delivery of services in 2020, contraceptive purchasing remained resilient throughout the forecasted periodNorth America to hold a considerable market share.
By geography, the global market for contraceptives is distributed in North America, South America, Europe, the Middle East and Africa, and the Asia Pacific. The North American region is anticipated to hold a significant share in the market to high awareness, particularly across the United States and Canada. Moreover, the higher purchasing power of the people, coupled with a well-established healthcare sector, will further supplement the region's share during the next five years.
Competitive InsightsThe players in the contraceptive market are implementing various growth strategies to gain a competitive advantage over their competitors in this market. Major market players have been covered along with their relative competitive strategies. The report also mentions recent deals and investments of different market players over the last few years. The company profiles section details the business overview, financial performance (public companies) for the past few years, key products and services being offered, and the recent deals and investments of these important players in the contraceptive market.
Pee Safe debuted Domina, a female condom, in an attempt to change the way India views contraception. This product can be worn for up to eight hours. Thus, the goal is to enable women to experience uninterrupted gratification without having to worry about their safety or pregnancy concerns.
Agile Therapeutics, Inc., a women's healthcare organisation, revealed the commercial release of Twirla (levonorgestrel and Ethinyl estradiol) transdermal process, a new non-daily, non-invasive contraceptive patch, in the United States.
- Contraceptive Pills
- Injectable Contraceptives
- Topical Contraceptives
- Intrauterine Devices (IUDs)
By Distribution Channel
By Age Group
- 15-24 years
- 25-34 years
- 35-44 years
- Above 44 years
- North America
- South America
- Middle East and Africa
- Saudi Arabia
- Asia Pacific
- South Korea
What is the estimated value of the Contraceptives Market?
What is the growth rate of the Contraceptives Market?
What is the forecasted size of the Contraceptives Market?
Who are the key companies in the Contraceptives Market?
|No. of Pages||140|
|Forecast Period||2020 - 2027|
| Estimated Market Value ( USD ||$ 23.52 billion|
| Forecasted Market Value ( USD ||$ 39.05 billion|
|Compound Annual Growth Rate||7.5%|
|No. of Companies Mentioned||12|
Table of Contents
1.1. Market Overview
1.2. Covid-19 Impact
1.3. Market Definition
1.4. Market Segmentation
2. Research Methodology
2.1. Research Data
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter's Five Forces Analysis
4.3.1. Bargaining Power of End-Users
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Contraceptives Market Analysis, by Product
5.2.1. Contraceptive Pills
5.2.2. Injectable Contraceptives
5.2.3. Topical Contraceptives
5.3.2. Intrauterine Devices (IUDs)
6. Contraceptives Market Analysis, by Distribution Channel
7. Contraceptives Market Analysis, by Age Group
7.2. 15-24 years
7.3. 25-34 years
7.4. 35-44 years
7.5. Above 44 years
8. Contraceptives Market Analysis, by Geography
8.2. North America
8.2.1. North America Contraceptives Market, By Product, 2020 to 2027
8.2.2. North America Contraceptives Market, By Distribution Channel, 2020 to 2027
8.2.3. North America Contraceptives Market, By Age Group, 2020 to 2027
8.2.4. By Country
8.3. South America
8.3.1. South America Contraceptives Market, By Product, 2020 to 2027
8.3.2. South America Contraceptives Market, By Distribution Channel, 2020 to 2027
8.3.3. South America Contraceptives Market, By Age Group, 2020 to 2027
8.3.4. By Country
8.4.1. Europe Contraceptives Market, By Product, 2020 to 2027
8.4.2. Europe Contraceptives Market, By Distribution Channel, 2020 to 2027
8.4.3. Europe Contraceptives Market, By Age Group, 2020 to 2027
8.4.4. By Country
8.5. Middle East and Africa
8.5.1. Middle East and Africa Contraceptives Market, By Product, 2020 to 2027
8.5.2. Middle East and Africa Contraceptives Market, By Distribution Channel, 2020 to 2027
8.5.3. Middle East and Africa Contraceptives Market, By Age Group, 2020 to 2027
8.5.4. By Country
184.108.40.206. Saudi Arabia
8.6. Asia Pacific
8.6.1. Asia Pacific Contraceptives Market, By Product, 2020 to 2027
8.6.2. Asia Pacific Contraceptives Market, By Distribution Channel, 2020 to 2027
8.6.3. Asia Pacific Contraceptives Market, By Age Group, 2020 to 2027
8.6.4. By Country
220.127.116.11. South Korea
9. Competitive Environment and Analysis
9.1. Major Players and Strategy Analysis
9.2. Emerging Players and Market Lucrativeness
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Vendor Competitiveness Matrix
10. Company Profiles
10.1. Allergan plc
10.2. ANSELL LTD.
10.3. Bayer AG
10.4. CooperSurgical Inc.
10.5. Merck & Co., Inc.,
10.6. Church & Dwight Co., Inc.
10.7. Veru Inc.
10.8. Mayer Laboratories, Inc.
10.9. Pfizer Inc.
10.10. Teva Pharmaceutical Industries Ltd.
10.11. Reckitt Benckiser Group plc
10.12. Mankind Pharma
10.13. Karex Berhad
- Allergan plc
- ANSELL LTD.
- Bayer AG
- CooperSurgical Inc.
- Merck & Co., Inc.,
- Church & Dwight Co., Inc.
- Veru Inc.
- Mayer Laboratories, Inc.
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Reckitt Benckiser Group plc